PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...

The Fairfield County Regional Panning Commission recently granted a $5.6 million building permit to build new hangars at the county airport.

Once a bustling hub for pilots during World War II, the Hangar Theatre has transformed from an aviation site into a vibrant stage, now echoing with 50 years of theatrical performances and serving ...

This is a recurring post, regularly updated with new information and offers. Although 2024 has ended, there may still be an opportunity to snag the next level of United Premier status for 2025. United ...

BTIG analyst Julian Harrison maintained a Hold rating on United Therapeutics (UTHR – Research Report) on January 21. The company’s shares ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...

Jim Flock Jr., an FAA-certified pilot and aircraft owner based in Atlanta, has flown to many of Georgia's privately and publicly-owned airports. As the president and qualifying broker of Flock ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.